ARA-290: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 9 sources cited
Overview
ARA-290 (cibinetide) is an 11-amino-acid synthetic peptide derived from the three-dimensional structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis or increasing red blood cell counts. It possesses potent anti-inflammatory, tissue-protective, and nerve-regenerative properties, with clinical trial data demonstrating benefits for small fiber neuropathy, sarcoidosis-associated neuropathy, and diabetic complications. It represents a paradigm shift in EPO-derived therapeutics — harnessing tissue protection without blood-thickening risks.
Mechanism of Action
ARA-290 binds to the innate repair receptor (IRR), a heteromeric complex formed by the EPO receptor (EPOR) and the beta-common receptor (βcR, also known as CD131). This receptor complex is distinct from the classical homodimeric EPOR that drives erythropoiesis, and it is preferentially expressed on injured, inflamed, or stressed tissues — meaning ARA-290 selectively targets damaged tissue rather than acting systemically. When ARA-290 activates the IRR, it triggers JAK2 phosphorylation and downstream activation of STAT5, PI3K-Akt, and NF-κB inhibitory pathways. The functional consequences include: suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); inhibition of apoptosis in stressed cells via Bcl-2 upregulation and Bad phosphorylation; promotion of efferocytosis (the clearance of dead cells by macrophages); and stimulation of tissue repair processes including angiogenesis and axonal regeneration. Critically, ARA-290 has no affinity for the classical homodimeric EPOR, meaning it produces zero erythropoietic effects — no increase in hematocrit, hemoglobin, or red blood cell mass. This eliminates the thromboembolic risks associated with EPO and makes ARA-290 safe for conditions where EPO's tissue-protective effects are desired but its blood-thickening effects are dangerous.
ARA-290 Benefits: What the Research Shows
- A Phase II clinical trial in small fiber neuropathy demonstrated significant improvement in corneal nerve fiber density (a validated surrogate for peripheral nerve regeneration) after 28 days of treatment — one of the first compounds to show objective nerve regrowth in humans.
- In sarcoidosis-associated small fiber neuropathy, ARA-290 improved neuropathy symptom scores more than placebo, including the autonomic score (29% versus 6% in one trial), but pain intensity improved about as much on placebo.
- Clinical data in type 2 diabetic patients showed metabolic improvements including reduced HbA1c, suggesting the IRR pathway has direct metabolic benefits beyond tissue repair.
- In mice with genetic diabetes, cibinetide improved impaired wound healing, including time to complete wound closure. No human wound-healing trial has been published.
- A preclinical study showed the ARA-290 peptide reduced infarct size by 50% at 24 hours in a rat coronary artery ligation model, demonstrating cardioprotective effects.
- Unlike EPO, ARA-290 produced no clinically significant changes in hematology measures in the published trials, consistent with separation of tissue-protective and erythropoietic activities.
ARA-290 Dosage
- Clinical trial dose for neuropathy: 4 mg subcutaneous injection daily for 28 days (the phase 2 trials in sarcoidosis neuropathy and type 2 diabetes); an earlier pilot used 2 mg intravenously three times per week for 4 weeks. This is the best-characterized human dosing protocol.
- Extended protocol: 4 mg SC daily for 12 weeks, used in one small trial in diabetic macular edema (9 patients).
- Dose-ranging: 1, 4 or 8 mg SC daily for 28 days were compared in the phase 2b sarcoidosis neuropathy trial; only the 4 mg dose significantly increased corneal nerve fiber area.
- Self-administered subcutaneously in clinical trial settings — patients were trained on SC injection technique and managed dosing at home.
- No food timing restrictions. Can be administered at any time of day.
- Research-grade reconstitution: add bacteriostatic water to lyophilized vial per label instructions. Typical concentration yields 2 mg per 0.5 mL injection.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
ARA-290 Side Effects & Safety
Known Side Effects
- Injection site reactions — possible with any subcutaneous injection, though the sarcoidosis trial reported no pain or local irritation at the injection site.
- Headache — reported by a small percentage of trial participants, typically mild.
- Mild gastrointestinal symptoms — occasional nausea reported, not dose-limiting.
- Upper respiratory tract infections — reported at similar rates in treatment and placebo groups, likely not treatment-related.
- Serious adverse events were rare, but in the type 2 diabetes trial two in the ARA-290 group were judged possibly related to the drug.
- No hematological changes — critically, no increase in red blood cells, hemoglobin, or hematocrit, confirming safety over EPO.
Safety Profile
ARA-290 was generally well tolerated in five small published Phase II trials involving about 180 participants in total. The complete absence of erythropoietic effects eliminates the most significant risk associated with EPO-derived compounds — blood thickening and thromboembolism. Most trials reported no serious adverse events, but in the type 2 diabetes trial two serious events in the ARA-290 group were judged possibly related to the drug. Contraindications are theoretical and precautionary: active malignancy (the IRR could theoretically protect tumor cells from apoptosis, though no evidence supports this), severe immunosuppression, and pregnancy/breastfeeding. Drug interactions are not well-characterized but are expected to be minimal given the peptide's targeted mechanism. The compound's selective activity on stressed/injured tissue provides an inherent safety advantage — healthy tissue with low IRR expression is largely unaffected.
What to Expect
Week 1: ARA-290 begins modulating the innate repair receptor in damaged tissues. Anti-inflammatory effects may produce subtle improvements in pain levels or discomfort, though nerve regeneration is not yet apparent. Weeks 2–4: Anti-inflammatory effects become more noticeable. Patients with neuropathic pain may experience meaningful reduction in symptoms. In diabetic mice, wound healing was faster. Corneal confocal microscopy (if performed) may show early signs of nerve fiber regeneration. Weeks 5–8: Nerve regeneration becomes more measurable. Clinical trials showed significant corneal nerve fiber density increases by this point. Pain reduction continues to improve. Metabolic markers (HbA1c in diabetics) may show improvement. Weeks 9–12: Maximum benefits from extended protocols. Nerve fiber regeneration continues. Improvements in autonomic function and sensory thresholds become established. Benefits may continue to accrue for weeks after cessation as regenerated nerve fibers mature.
Common Stacks
BPC-157
BPC-157 promotes angiogenesis and growth factor expression through complementary pathways (VEGF, FGF), synergizing with ARA-290's anti-inflammatory and tissue-protective effects for comprehensive wound and nerve healing.
TB-500 (Thymosin Beta-4)
TB-500's cell migration and anti-inflammatory effects via actin regulation complement ARA-290's tissue-protective and nerve-regenerative properties, covering structural repair and cytoprotection simultaneously.
GHK-Cu
GHK-Cu promotes collagen synthesis, anti-inflammatory gene expression, and antioxidant activity — supporting the tissue environment that ARA-290 is working to protect and regenerate.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). Protect from light and moisture. After reconstitution with bacteriostatic water, refrigerate and use within 28 days. Do not freeze reconstituted solution. Shelf life of unreconstituted powder is approximately 24 months when properly stored.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Culver DA, Dahan A, Bajorunas D, et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017.
- Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013.
- Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015.
- Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012.
- Lois N, Gardner E, McFarland M, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med. 2020.
- Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008.
- Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004.
- Ahmet I, Tae HJ, Juhaszova M, et al. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med. 2011.
- Bitto A, Irrera N, Pizzino G, et al. Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochim Biophys Acta Mol Basis Dis. 2018.
Related Peptides
Track ARA-290 in Your Protocol
Log your ARA-290 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free